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a  b  s t  r  a  c t
A  reliable  method of  directly measuring  endogenously generated  nitric  oxide  (NO) in  real-time  and in
various  brain regions is  presented.  An  extensive  characterisation  of a  previously  described  amperometric
sensor  has  been  carried  out in  the  prefrontal cortex  and  nucleus accumbens of  freely  moving rats.  Systemic
administration  of saline caused  a  transient increase  in  signal  from baseline levels  in  both the  prefrontal
cortex  (13  ± 3 pA, n  =  17) and  nucleus  accumbens (12 ±  3 pA, n  = 8).  NO levels in  the  prefrontal cortex
were  significantly increased  by 43 ± 9  pA  (n  = 9)  following administration of  l-arginine. A  similar  trend
was  observed  in  the nucleus accumbens,  where  an  increase  of  44  ±  9 pA (n  = 8)  was  observed  when  com-
pared  against baseline  levels. Systemic injections  of  the  non-selective  NOS inhibitor  l-NAME  produced a
significant  decrease in  current  recorded  in  the prefrontal  cortex  (24  ± 6 pA, n  = 5)  and nucleus  accumbens
(17  ± 3 pA, n  =  6). Finally  it  was  necessary  to validate the sensors functionality in vivo by investigating
the  effect  of  the  interferent ascorbate on  the  oxidation  current.  The  current  showed no variation in  both
regions  over  the  selected  time interval of  60  min,  indicating  no  deterioration  of  the  polymer  membrane.
A  detailed comparison identified significantly greater affects  of administrations on  NO sensors  implanted
in  the striatum than those inserted in  the prefrontal  cortex  and  the nucleus  accumbens.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Since its emergence as a  signalling molecule in the brain 20
years ago, nitric oxide (NO) has been implicated in  many different
functions that are determined by the source of the nitric oxide syn-
thase (NOS) enzyme used in its synthesis. Three isozymes have so
far been identified; endothelial NOS (eNOS), neuronal NOS (nNOS)
and inducible NOS (iNOS) (Alderton et al., 2001; Bruckdorfer, 2005;
Kelm, 1999; Kiechle and Malinski, 1993). Endothelial cells are prob-
ably the major, if  not the sole, location of eNOS in  the brain with
emerging evidence of its  role in regulating brain function, inde-
pendent of its role in the vasculature (Garthwaite, 2008). Neuronal
NOS is the most abundantly present isoform in the brain and is
tightly associated with NMDA receptor function on post-synaptic
membranes. The inducible form, which is Ca2+ independent and
produced in large amounts in response to  an external stimulus such
as infection or inflammation, carries out its role following release
from macrophages (Bruckdorfer, 2005).
NO’s diverse functions include a neurological function in
synaptic plasticity, neurotransmission, learning and memory
(Garthwaite, 2008; Wass et al., 2006a,b), in addition to having a
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primary role in non-specific immunity (Bruckdorfer, 2005), penile
erection (Escrig et al., 1999; Mas  et al., 2002) and platelet aggrega-
tion inhibition (Radomski et al., 1990). While NO is responsible for
normal synaptic transmission, excess levels of NO  have been por-
trayed  as being neurotoxic (Barth et al., 1997; Espey et al., 2002).
Glutamate neurotoxicity is hypothesised to occur primarily due to
release of NO from glial cells, via activation of the ionotropic glu-
tamate NMDA receptor (Dawson et al., 1996). Barth et al. (1997)
found that NO produced in  response to ischaemia and mediated
by glutamate release can cause neuronal cell death, effects which
were largely prevented by  use of NOS inhibitors.
It  is hypothesised that the prefrontal cortex serves a specific
function in cognitive control in  the brain; impairments of this brain
region have been implicated in  schizophrenia giving rise to neg-
ative  symptoms and cognitive dysfunctions associated with the
disease (Fejgin et al., 2008; Miller and Cohen, 2001; Tzschentke,
2001).  The nucleus accumbens which is part of the ventral stria-
tum is assumed to play a  role in reward, emotion and addiction
(Saul’skaya and Fofonova, 2009; Saul’skaya et al., 2008; Saulskaya
and  Fofonova, 2006; Savel’ev and Saul’skaya, 2007; Yananli et al.,
2007) and it too is postulated to have a  function in the pathophys-
iology of schizophrenia. Recent findings have postulated that the
NO pathway may constitute an interesting target for novel phar-
macological therapies in schizophrenia and possibly play a  role
in  the pathophysiology of the disorder. However, this contention
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rests on indirect evidence as suitable tools for the real-time detec-
tion of NO in vivo have, until recently, been lacking (Palsson et al.,
2009). This has also been highlighted recently by Garthwaite, who
expressed a great need for  a  reliable method of directly measuring
endogenously generated NO in tissues with the necessary sensi-
tivity or spatial and temporal precision (Garthwaite, 2008). We
have previously reported the in vitro (Brown et al., 2009; Brown
and Lowry, 2003) and in vivo (Finnerty et al., 2012) character-
isation of a Nafion®-modified Pt sensor designed for real-time
monitoring of brain extracellular NO. In vitro findings confirmed
that the Nafion®(5/2) sensor had a response time suitable for in  vivo
monitoring, linearity over the relevant concentration range for
NO,  freedom from protein and lipid fouling, and minimal inter-
ference from a variety of endogenous species, including ascorbic
acid, dopamine and serotonin over physiologically relevant con-
centration ranges. A  detailed in  vivo characterisation was  carried
out in the striatum of wistar rats and significant NO changes were
recorded against baseline following administrations of stock NO,
l-arginine and l-NAME. Ascorbate selectivity studies confirmed
minimal deterioration of the Nafion®-modified surface and the
stability of the sensor was analysed over 8 days confirming no sig-
nificant change in baseline. We  investigated the application of the
NO sensor in a study carried out utilising the psychotomimetic drug
phencyclidine hydrochloride (PCP), which was found to  induce
a dose-dependent increase in prefrontal cortex NO  levels, thus
corroborating previous indirect evidence of this effect of PCP. In
addition, the PCP-induced elevation of NO could be counteracted
by  pretreatment with the NOS inhibitor, l-NAME, in a dose that has
previously been shown to block the behavioural effects of PCP in
translational animal models of schizophrenia (Klamer et al., 2004a,
2001; Palsson et al., 2009; Wass et al., 2006a,b). This study has pro-
vided the first direct biochemical evidence for an  involvement of
NO in the effects of the NMDA receptor antagonist PCP.
In  the present study an extensive characterisation of the
Nafion®(5/2)-modified Pt sensor was carried out in  the prefrontal
cortex and nucleus accumbens of awake freely moving rats. These
two brain regions were chosen due to their high density of NMDA
receptors (Monaghan and Cotman, 1985) and their hypothesised
roles in the pathophysiology of schizophrenia (Fejgin et al., 2008).
Secondly, a comparative analysis was undertaken between the
Nafion®(5/2)-modified Pt sensors implanted in the prefrontal cor-
tex, nucleus accumbens and striatum.
2. Materials and methods
2.1. Chemicals and solutions
All chemicals used throughout the experiments were purchased
from Sigma Chemical Co. (Dublin, Ireland). A 0.9% solution of saline
was prepared by dissolving 0.9 g NaCl in 100 mL  doubly distilled
water. In all cases, unless otherwise noted all systemic admin-
istration of l-arginine (300 mg  kg−1), l-NG-nitroarginine methyl
ester hydrochloride (l-NAME, 30 mg kg−1), and sodium ascorbate
(2 g kg−1) were made up in  a solution of 0.9% saline.
2.2. NO sensor preparation
Nafion®(5/2)-coated Pt  disk electrodes were made from
Teflon®-insulated platinum/iridium (Pt/Ir 90%/10%) wire (125 m
bare diameter 5T, Advent Research Materials, Suffolk, UK). The elec-
trodes were approximately 4 cm in length and were prepared by
carefully cutting 2 mm  of Teflon® insulation from one end of the
wire and soldering to this end a gold clip which provided rigidity
and  electrical contact. The other end of the wire acted as the active
(disk) surface. The electrode was modified as previously described
(Brown et al., 2009; Brown and Lowry, 2003; Finnerty et al., 2012).
2.3. Systemic administrations
All systemic administrations were carried out in 1 mL  saline by
intraperitoneal (i.p.) injection.
2.4. In vivo implantation and surgery protocol
Male Wistar rats (Biomedical Facility, University College Dublin,
Ireland) weighing between 200 and 300 g were housed in a tem-
perature (17–23 ◦C), humidity and light-controlled (12 h light,
12 h dark cycle) environment with access to food ad libitum
prior to surgery. NO sensors were implanted following a previ-
ously described procedure (Lowry et al., 1997). Coordinates for
the prefrontal cortex and nucleus accumbens with the skull lev-
elled between bregma and lambda, were: A/P + 3.2, M/L ± 0.8 from
bregma and D/V − 4.2 from dura and A/P +  1.85, M/L  ± 1.3 from
bregma and D/V − 6.8 from dura respectively (Paxinos and Watson,
1998). A reference and auxiliary electrode (8T Ag wires, 200 m
bare  diameter) were placed in the cortex. The reference potential
provided by  the bare Ag wire in brain tissue is very similar to that
of  the saturated calomel electrode (SCE) used in the in vitro char-
acterisation (O’Neill et al., 1998). The electrodes and probe were
fixed to the skull with dental screws and dental acrylate (Asso-
ciated Dental Products, Swindon, UK). The rats were anesthetised
with the volatile anaesthesia Isoflurane, placed in  a Kopf stereotaxic
instrument and kept on a  heating pad to prevent hypothermia. A
1  mL/kg injection of the opioid analgesic buprenorphine is  admin-
istered subcutaneously (s.c.) 30 min  after the end of the surgery
and the animal allowed to rest. The animal is monitored for the
next few hours, before being transferred to a holding bowl where it
remains for the duration of the experiment. The animal is allowed
to recover for  at least 24 h prior to  connection to the potentiostat.
The desired potential (+900 mV vs. Ag  wire) is then applied to the
NO sensor and the current is allowed to stabilise for approximately
24 h. Following this period of stabilisation, in  vivo measurements
were commenced. All experimental procedures were performed
under license in accordance with the European Communities Regu-
lations 2002 (Irish Statutory Instrument 566/2002 and U.K. Animals
(Scientific Procedures) Act 1986).
2.5. Instrumentation and software
Constant potential amperometry was performed using pre-
viously described methods (Brown et al., 2009; Finnerty et al.,
2012). All data presented had baselines normalised to zero to show
the change in current (I)  and reported concentration changes
are based on a previously reported protocol (Finnerty et al.,
2012). The significance of differences observed was estimated
using the Student’s t-test for paired or unpaired observations
where appropriate. Two-tailed levels of significance were used
with p <  0.05 considered to be significant. All data are presented
as  mean ± standard error (SEM), with n = number of sensors
implanted in 8 animals (saline – prefrontal cortex), 4 animals
(saline –  nucleus accumbens), 5 animals (l-arginine – prefrontal
cortex), 4  animals (l-arginine – nucleus accumbens), 5 animals
(l-NAME – prefrontal cortex), 4  animals (l-NAME – nucleus
accumbens) 6 animals (ascorbate – prefrontal cortex) and 5 ani-
mals (ascorbate – nucleus accumbens). The sample data presented
in Figs. 1–4 has been normalised and transformed to the average
response obtained for the respective treatments. This removes both
inter  electrode and inter animal variability by ensuring that the
Author's personal copy
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Fig. 1. Typical examples of  the effect of saline administration (1 mL  i.p.
injection) monitored in rat prefrontal cortex (top, average pre-injection base-
line = 317 ± 14 pA, n = 17) and rat nucleus accumbens (bottom, average pre-injection
baseline = 324 ± 37 pA, n = 8) with a Nafion®(5/2)-modified Pt sensor. Time zero indi-
cates point of injection.
presented current and concentration changes are representative
of  the data from all the animals used in  each study.
2.6. Experimental conditions
All experiments were carried out with the animal in its home
bowl. Implanted electrodes were connected to the potentiostat
through a six-pin Teflon® socket and a  flexible screened six core
cable which was mounted through a  swivel above the rats head
(Semat Technical) at least 7–8  h prior to the start of the first exper-
iment each day. This arrangement allowed free movement of the
animal.
2.7. Voltammetry techniques in vivo
All in vivo experiments utilised constant potential amperometry
which involves the application of a constant voltage. The resulting
current is directly proportional to  the concentration of the analyte
at  any given time. NO was detected by holding the implanted sensor
at  the oxidation potential of +900 mV (vs.  Ag wire) which has been
previously characterised as the optimum potential for NO  detection
(Brown, 2003; Brown et al., 2009).
3. Results and discussion
3.1. Systemic administrations
Since all administrations were by i.p. injection it was  important
to examine the effect of normal saline administrations (0.9%) on the
oxidation current. We have previously reported a  significant but
short lived change (22 ± 3 pA, p  < 0.001, n =  9) from baseline levels
in NO sensor’s implanted in  the striatum of Wistar rats following
Fig. 2.  Typical examples of the effect of l-arginine administration (300 mg kg−1,
1 mL i.p. injection) monitored in rat prefrontal cortex (top, average pre-injection
baseline = 394 ± 94  pA, n = 9) and rat nucleus accumbens (bottom, average pre-
injection baseline = 245 ± 25  pA, n  = 8) with  a Nafion®(5/2)-modified Pt sensor. Time
zero indicates point of injection.
saline injection (Finnerty et al., 2012). Similar initial and brief injec-
tion effects have also been observed for tissue O2 (Bolger et al.,
2011) and regional cerebral blood flow (rCBF) (Lowry and Fillenz,
2001) during the injection of saline, with a comparable return
to  baseline levels. A significant increase in the recorded current
(13 ± 3 pA, p <  0.001, n = 17) was observed in the prefrontal cortex,
reaching a  maximum level after 5 ± 1 min  (n = 17) and returning
to  a  baseline level after 12 ± 2 min. This short lived increase in
oxidation current corresponded to a concentration change of ca.
8  ± 2 nM.  A similar affect was  observed in the nucleus accumbens
following saline administrations. A transient increase in oxidation
current (12 ± 3 pA, n  = 8)  occurred after 4 ± 2  min. This resulted in
a  significant increase from baseline (p <  0.05) that represented a
concentration change of 7 ± 4 nM (n =  8). The current returned to
a  baseline level after 8 ± 3 min. Typical examples of the effect of
saline administration in both regions are shown in Fig. 1. The stress
of  the i.p. injection stimulates neuronal activation (Vahabzadeh
and  Fillenz, 1994), increasing rCBF and thus O2,  with the supply
of  the latter exceeding utilisation. The observed increase in  blood
flow  can be attributed to vasodilation brought about by NO through
its physiological function as the EDRF (Ignarro et al., 1987; Palmer
et al., 1987). The different roles that NO has to play in the body are
dependent on which type of NOS enzyme is used in its synthesis.
The constitutive forms (endothelial (eNOS) and neuronal (nNOS))
which are activated by  Ca2+,  followed by binding to  the protein
calmodulin, exert their effects through blood flow and neurotrans-
mission respectively (Marletta, 1993). These findings corroborate
previous reports that were carried out in  the striatum of freely
moving rats utilising the amperometric NO sensor (Finnerty et al.,
2012).
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Fig. 3. Typical examples of  the  effect of l-NAME administration (30  mg kg−1, 1 mL
i.p. injection) monitored in rat prefrontal cortex (top, average pre-injection base-
line = 311 ± 38 pA, n = 5) and rat nucleus accumbens (bottom, average pre-injection
baseline = 407 ± 107 pA, n  = 6) with a Nafion®(5/2)-modified Pt sensor. Time zero
indicates point of injection.
The reaction of l-arginine with molecular O2 in  the presence
of NO synthase results in  the formation of NO and l-citrulline
in equimolar quantities. Recent studies have demonstrated that
arginine availability is an important condition for the physiologi-
cal functioning of the nitroergic system (Do et al., 2002; Savel’ev
Fig. 4. Typical example of the effect of an i.p injection of sodium ascorbate (2 g kg−1,
average pre-injection baseline = 359 ± 56 pA, n =  13) on currents monitored in  pre-
frontal cortex with a Nafion®(5/2)-modified Pt sensor and carbon paste electrode
(CPE). Time zero indicates point of injection. Inset: Typical example of the effect of an
i.p. injection of sodium ascorbate on a 60 min  response of a Nafion®(5/2)-modified
Pt sensor implanted in the prefrontal cortex.
and Saul’skaya, 2007). Indirect reports confirm the antioxidant
effects of l-arginine in the early and late stages of ischaemia
(Maksimovich et al., 2006) and its reduction in brain edema forma-
tion and improvement of cortical blood flow in the early phase after
a brain trauma (Lundblad and Bentzer, 2007). Previously our group
has confirmed in real-time that both systemic and local l-arginine
administration significantly increased the NO sensor’s signal in the
striatum of Wistar rats compared to pre-administration baseline
levels (Brown et al., 2009; Finnerty et al., 2012). Typical exam-
ples of the effect of l-arginine injections in  the prefrontal cortex
(top) and nucleus accumbens (bottom) are detailed in  Fig. 2. A
significant increase was observed in  both the prefrontal cortex
(43 ± 9 pA, p <  0.01, n =  9) and nucleus accumbens (44 ± 9, p < 0.01,
n  = 8) in comparison to pre-injection baselines. These corresponded
to concentration changes of 27 ± 6  nM (n =  9) and 28 ± 5 nM (n  = 8)
respectively. The maximum increase was recorded at 42 ± 9 min
(n =  9) in  the prefrontal cortex before returning to baseline levels
after 136 ± 15 min  (n  = 9). In the nucleus accumbens the maximum
response was  achieved after 65 ± 10 min  (n =  8) and returned to
pre-injection levels after 153 ± 12 min  (n =  8). These observations
confirm that the NO sensor is responding to increased produc-
tion of endogenous NO in both regions validating previous findings
from other groups who reported an increase in NO current accom-
panying l-arginine perfusion, using an  amperometric NO sensor
implanted in the hippocampus of rats (Heinzen and Pollack, 2003,
2002). Previously, similar reports have detailed carbon fibre micro-
electrodes utilised for NO  measurements in the corpus cavernosum
of  urethane-anaesthetised rats recorded enhancements in  the NO
signal following arginine administration (Escrig et al., 1999; Mas
et al., 2002). Also, Carvalho et al. (2004) reported real-time in vitro
measurements of NO production in erythrocytes using a  commer-
cial NO sensor during stimulation by l-arginine.
l-NAME is a non-selective nitric oxide synthase (NOS) inhibitor
which acts by competing with l-arginine for its binding site on
the NOS enzyme (Alderton et al., 2001). Microdialysis investi-
gations have provided indirect evidence relating to decreases in
co-product l-citrulline levels in  the dorsal striatum following local
infusion of various NOS inhibitors, l-NAME (Ohta et al., 1994) and
in the nucleus accumbens following N-nitro-l-arginine (Saulskaya
and Fofonova, 2006). l-Citrulline displays much greater chemi-
cal stability than NO which has resulted in  the development of
a  series of indirect methods based on studies of citrulline syn-
thesis in the nucleus accumbens for assessing NO production
(Saul’skaya and Fofonova, 2009; Saul’skaya et al., 2008; Savel’ev and
Saul’skaya, 2007). Recently we reported a  significant decrease in
NO (91 ± 19 pA, p <  0.05, n = 4)  compared to baseline levels follow-
ing l-NAME administration in  the striatum of Wistar rats (Finnerty
et  al., 2012). A typical example of the effects of a  30  mg kg−1 i.p.
injection in both the prefrontal cortex and nucleus accumbens
are  illustrated in Fig. 3. The signal (I)  decreased significantly by
24 ± 6 pA (n =  5, p  < 0.05) and 17 ± 3 pA (n  = 6, p <  0.01) respectively
compared to baseline levels. A  maximum response was  observed at
51 ± 12 min  (n = 5)  in the prefrontal cortex that returned to baseline
levels after 184 ± 72 pA (n =  5). A  similar observation was  reported
in the nucleus accumbens with a  maximum decrease occurring
at  60 ± 6 min  (n  = 6) and returning to pre-injection levels after
171 ± 27 min (n =  6). The current changes corresponded to concen-
tration changes of 15 ± 4 nM (n  = 5) and 11 ± 2  nM (n =  6) in  the
prefrontal cortex and nucleus accumbens respectively. These find-
ings  corroborate investigations undertaken by Escrig et al.  (1999)
in the corpus cavernosum whereby local and systemic administra-
tions of l-NAME caused a decrease in  NO levels. Indirect reports
detailing l-NAME have shown that the NOS inhibitor attenuates
or completely blocks the effects of phencyclidine hydrochloride
(PCP), an  NMDA receptor antagonist that is assumed to carry out its
actions through an  NO-mediated mechanism (Wass et al., 2006a,b;
Author's personal copy
N.J. Finnerty et al.  /  Journal of Neuroscience Methods 209 (2012) 13– 21 17
Wiley, 1998). A number of behavioural studies incorporating a
series of different paradigms have confirmed this, for example,
prepulse inhibition, which is the reduction in startle amplitude to
a  startling stimulus when this stimulus is immediately preceded
by  a weaker pre-stimulus (Klamer et al., 2001, 2004b). Another is
latent inhibition, which is a referral to a  phenomenon whereby pre-
exposure to a stimulus weakens the subsequent association of that
stimulus with a reinforcer in classical conditioning (Klamer et al.,
2005; Palsson et al., 2005). We  have recently reported direct evi-
dence that 10 mg  kg−1 l-NAME injections inhibit NO production
following systemic administration of PCP (Palsson et al., 2009) con-
firming the postulations of the previous behavioural investigations.
Other paradigms reported include the elevated plus-maze which is
based on exploratory behaviour of rats. NO is believed to play a role
in learning and memory and l-NAME is shown to  induce a  learning
deficit in this avoidance learning test (Da  Cunha et al., 2005). Since
nitric oxide has been characterised as the EDRF, it is very closely
associated with CBF and cerebrovasodilation. A  number of existing
reports have reported that l-NAME induced a  reduction in levels of
CBF  that were increased following a period of hyperbaric oxygen
exposure by a nitric oxide mediated mechanism (Demchenko et al.,
2000, 2001; Hagioka et al., 2005). Yan et al.  (2003) also reported
a  decrease in CBF in  response to intravenous infusion of the NO
synthase inhibitor at doses of 1, 3, 10 and 30 mg  kg−1.
3.2. Interference studies
Previously the Nafion®(5/2)-modified Pt NO  sensor demon-
strated excellent selectivity towards NO in  vitro against a wide
range of electroactive interferents (e.g. ascorbic acid, dopamine,
DOPAC, NO2−, serotonin) found endogenously in  brain extracellu-
lar fluid (Brown et al., 2009). In vivo investigations in  the striatum
of  freely moving rats displayed excellent rejection characteris-
tics against ascorbate (Finnerty et al., 2012), the most abundantly
present interferent reported in the ECF with a hypothesised con-
centration of ca. 500 M (Miele and Fillenz, 1996). It is  imperative
to  confirm that the Nafion® membrane has not degraded when
placed in the in vivo environment and that the sensor exhibits sim-
ilar selectivity characteristics to those recorded in  vitro (Brown
et al., 2009; Brown and Lowry, 2003). With its high concentra-
tion and ease of oxidation, ascorbate is probably the simplest
molecule to detect and monitor in brain ECF using in  vivo voltam-
metry techniques (Lowry and O’Neill, 2006; O’Neill et al., 1998). For
these reasons it was important to investigate the effect of systemic
administrations of ascorbate on the Nafion®-modified Pt sensor
current in both the prefrontal cortex and nucleus accumbens. The
current was monitored over a  60 min  period as previous inves-
tigations have reported this time frame allows for a  maximum
response to occur (Finnerty et al., 2012; Lowry et al., 1996). It is
hypothesised that any effect following ascorbate injection will have
occurred within this period. Fig. 4 (inset) illustrates this effect from
a Nafion®(5/2)-modified Pt NO  sensor implanted in the nucleus
accumbens. There was a  slight decrease in  the oxidation current
over the course of ascorbate injections in both brain regions that
can be attributed to baseline drift recorded over the 60 mins. There
was no significant difference in signal against baseline levels in
the prefrontal cortex (−8 ± 16 pA, p >  0.05, n =  13) and the nucleus
accumbens (−16 ± 17 pA, p > 0.05, n =  10) recorded over the 60 min
period. Fig. 4 displays a comparison between a typical example of
the effect of ascorbate injection (2 g kg−1)  on a  carbon paste elec-
trode and the Nafion®(5/2)-modified Pt NO sensor implanted in  the
prefrontal cortex. It is clearly evident that there is a  difference in
the signal elicited from both sensors following administration of the
interferent. This comparison provides validation that ascorbate has
reached both sensors and no increase at the Nafion®(5/2)-modified
Pt  NO sensor was observed, confirming that the NO sensor’s surface
has remained intact. A similar observation was  noted in the nucleus
accumbens. Collectively these results corroborate previous investi-
gations undertaken in the striatum of freely moving rats (Finnerty
et al., 2012).
3.3. Regional comparisons
Table 1 summarises the in vivo characterisation data for
Nafion®(5/2)-modified sensors implanted in the striatum, pre-
frontal cortex and nucleus accumbens of freely moving rats. It is
apparent from these investigations that alternative sources of NO
production may be responsible for differences observed between
brain regions. The constitutive isoforms of NOS (eNOS and nNOS)
are the primary source of NO production in the brain lending sup-
port to its hypothesised function as a signalling molecule in the
central nervous system. iNOS is  primarily linked with pathological
situations and is rarely present at tonic levels but is expressed in
various cell types such as macrophages and microglia (Garthwaite,
2008). It is imperative that we consider regional variations in
determining parameters such as NOS activity and NOS expression,
highlighting the fact that there may  be multiple sources of NO
production and inhibition within a tissue matrix. In the dorsal stria-
tum, projection neurons comprise 90% of all the cells; however,
interneurons comprise only 10% of striatal cells and are implicated
in  regulating striatal projection function. It is the interneurons that
are the primary source of nNOS in this brain region (Kawaguchi and
Emson, 1996; Marin et al., 2000).
The ventral striatum (nucleus accumbens) contains NO gen-
erating interneurons that receive excitatory glutamatergic and
dopaminergic inputs from the hippocampus and ventral tegmental
area respectively (Saulskaya and Fofonova, 2006). A  high density
of NMDA receptors has been confirmed in  the prefrontal cortex
(Monaghan and Cotman, 1985) and it is postulated that NO  exerts
strong influence on glutamatergic neurotransmission by directly
interacting with the receptor (Bernstein et al., 2005). Various other
reports have indicated that NOS activity was  decreased in  the hip-
pocampus of aged rats but not in the cortex or cerebellum (Mollace
et al., 1995; Vallebuona and Raiteri, 1995), however, alternative
investigators reported increased activity in both the hippocampus
and cerebellum of aged rats (Chalimoniuk and Strosznajder, 1998).
These findings have all been quantified by indirect methods which
is  a  major disadvantage of the vast majority of existing analyti-
cal  techniques. The Nafion®(5/2)-modified Pt NO sensor described
here  represents a major advancement in measuring physiologically
meaningful NO levels in  real-time and over extended periods.
Saline administrations resulted in transient increases from base-
line that had returned to pre-injection baselines within a 15 min
time frame across all brain regions. It is a well accepted phe-
nomenon that injection stress causes an increase in neuronal
activation which is closely linked to CBF (Vahabzadeh and Fillenz,
1994). The larger blood vessels are supplied with nitrergic nerves
that once activated, result in NO release, vasodilation and increased
blood flow (Garthwaite, 2008; Toda and Okamura, 2003). Fig. 5 (top)
compares the effect of saline injections on the oxidation current
recorded in the three regions with an elevated response observed in
the striatum. A significant difference (p <  0.05) was observed when
comparing the current changes in the striatum (22 ± 3, n = 9)  and
nucleus accumbens (12 ± 3 pA, n = 8)  following injections. No sig-
nificant difference (p >  0.05) was observed between the striatum
and  prefrontal cortex (13 ± 3 pA, n =  17) or between the prefrontal
cortex and nucleus accumbens in terms of I  changes from base-
line levels. A number of factors must be taken into account when
interpreting these findings. The NO may  be generated from eNOS
located in the microvascular network and capillary circulation
that  can be attributed to a rise in  CBF following stress brought
about  by systemic administration. The implantation site of the
Author's personal copy
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Nafion®(5/2)-modified Pt NO sensor’s may  be situated in closer
proximity to vasculature circuitry when inserted into the striatum
giving rise to the larger NO signals recorded in this region. This may
not be the case for the sensors implanted in  the nucleus accum-
bens and prefrontal cortex, providing a possible explanation for
the different responses following saline administrations. A similar
effect has been observed using carbon paste electrodes for real-time
measurements of oxygen whereby, the concentration of oxygen
observed can vary depending on the orientation of the electrode rel-
ative to the blood vessels and metabolically active sites, and on the
depth of penetration into the tissue (Baumgärtl et al., 1989). Since
the dimension (typically 100–200 m)  of carbon paste electrodes
are greater than the scale of a capillary zone (ca. 70 m) (Silver,
1965), an average tissue O2 level is detected (Bolger et al., 2011).
This may  translate across to observations reported here with the
NO sensor since the three-dimensional geometry of the capillary
circulation would be just as well suited for delivering NO  glob-
ally to the electrode as it is for delivering O2 (Garthwaite, 2008).
Other possible sources could be from postsynaptic NO production
derived from nNOS, followed by diffusion into the extracellular
space. This is a  unique property that NO possesses over conven-
tional neurotransmitters in  that being a gaseous molecule it can
diffuse freely between membranes and has functions both intra-
cellularly and extracellularly. Kennedy (2000) reported that typical
excitatory synapses in the brain could have ca.  50 NMDA recep-
tors dispersed over a  400-nm-diameter postsynaptic density. Since
NMDA receptors display a  high association with nNOS, there is a
strong possibility that they are a contributing factor to our observa-
tions. Further evidence provided by Monaghan and Cotman confirm
high NMDA densities in the striatum, prefrontal cortex and nucleus
accumbens of rats (Monaghan and Cotman, 1985).
Systemic administrations of the precursor l-arginine and the
NOS inhibitor l-NAME displayed contrasting affects in  the different
brain regions investigated. Studies in recent years have demon-
strated that arginine availability is an  important condition for the
functioning of the nitrergic system (Savel’ev and Saul’skaya, 2007).
Tsikas et al.  (2000) reported arginine saturation in cells causes the
precursor to be present at concentrations far exceeding the Km
value. A topic that instigates much discussion is why supplemen-
tation of the substrate enhances NO production in vivo. It is a well
documented phenomenon referred to as the “arginine paradox”.
In  the present study l-arginine produced long lasting effects in
both the prefrontal cortex and nucleus accumbens that returned to
pre-injection levels within a 180 min  period. There was  no signifi-
cant difference (p > 0.05) between the three brain regions following
systemic administrations as illustrated in Fig. 5 (middle), how-
ever, the striatal current returned to pre-injection levels much
faster than the prefrontal cortex and nucleus accumbens. This is
clearly evident from Table 1 and may  be attributed to differences
between brain regions. Indirect measurements of NO (nitrite and
nitrate detection) following l-arginine administration have been
well documented using the microdialysis technique. Local (1 mM)
and systemic (500 mg kg−1)  administrations sufficiently induced
an enhancement of NO production in the rat cerebellum (Yamada
and Nabeshima, 1997). However, Hara et al. reported contradic-
tory findings from the hippocampus and striatum using a similar
indirect measurement. 500 mg  kg−1 injections of l-arginine sig-
nificantly increased extracellular hippocampal nitrite and nitrate
levels in comparison to saline administrations. In complete con-
trast to our findings, they found that 500 mg  kg−1 had no effect
on the extracellular levels of the NO metabolites in the striatum
(Hara et al., 2004). Their investigations postulate that the striatum
might be less responsive to exogenous l-arginine in enhancing NO
production via NOS than the hippocampus. The direct measure-
ments using our Nafion®(5/2)-modified Pt NO sensor suggest a very
contradictory function in the striatum with sufficient detection
Author's personal copy
N.J. Finnerty et al.  /  Journal of Neuroscience Methods 209 (2012) 13– 21 19
of increases in NO levels (71 ± 14 pA, n =  6). Although there were
reduced responses observed in  the prefrontal cortex (43 ± 9  pA,
n  = 9) and nucleus accumbens (44 ± 9 pA, n = 8), they did not differ
significantly from the striatum suggesting that the arginine para-
dox  might not be equally applicable in all regions of the brain.
Fig. 5 (bottom) and Table 1 detail the varying effect of
l-NAME administration on the Nafion®(5/2)-modified Pt NO sen-
sor in all three brain regions. There are significant differences
(p < 0.01) reported between the striatum (−91 ± 19  pA,  n =  4) and
the prefrontal cortex (−24 ± 6 pA, n =  5)  and nucleus accumbens
(−17 ± 3 pA, n = 6)  respectively. No  significant difference (p > 0.05)
was observed between the prefrontal cortex and nucleus accum-
bens. One possible explanation for the regional variations may
be due to the heterogenous distribution of NOS in the rat brain
that affects determining parameters such as NOS expression and
NOS inhibition within the tissue matrix. Various groups have pro-
vided indirect evidence of the effect of the NOS inhibitor on NO
levels in the prefrontal cortex using microdialysis investigations
(Laitinen et al., 1994, 1997; Pepicelli et al., 2004). l-NAME and
another NOS inhibitor l-NARG failed to diminish cGMP levels in
the frontal cortex of rats, however, these findings are difficult to
interpret as they provide indirect evidence of NO  activity in the
region. They may  provide some corroboration with our investi-
gations since significantly reduced NO inhibition was  observed
in  the prefrontal cortex in  contrast to  the striatum. Contrasting
evidence provided by Fedele and Raiteri (1999) in the rat cerebel-
lum and hippocampus reported that reterodialysis administration
of  NOS inhibitors markedly decreased extracellular cGMP in  both
regions. Collectively this evidence postulates that NOS inhibition
in the rat prefrontal cortex is controlled in  a different way from
what occurs in other brain regions, such as the cerebellum and
hippocampus. Citrulline monitoring is extensively utilised as an
alternative method of determining NO fluctuations indirectly in
various brain regions. Ohta et al. (1994) have reported decreases
in  citrulline in the striatum following local infusion of l-NAME, a
finding which lends further support to our observations. Saulskaya
and Fofonova (2006) extend these observations by demonstrating
that local administrations of a NOS inhibitor (l-NA) in  the nucleus
accumbens reduces citrulline levels suggesting that there may  be
tonic levels of NOS present in the nucleus accumbens, that initiate
the formation of the co-product of NO  production during homeo-
stasis.
Considering that the NO sensors were implanted bilaterally
in left and right hemispheres of the nucleus accumbens, it  was
of interest to compare the effect of injections on contralateral
placement in this brain region. Saline injections resulted in tran-
sient increases in  NO signal in both the left (19 ± 1 pA, n = 2) and
right (10 ± 4 pA, n =  6) hemispheres. There was no significant dif-
ference (p > 0.05) recorded between the two. A  similar observation
was reported for l-arginine injections. There was no significant
difference (p > 0.05) between responses from the Nafion®(5/2)-
modified Pt sensors implanted in  the left (53 ± 9  pA, n =  2) and
right (44 ± 11 pA, n =  6) sides of the nucleus accumbens. l-NAME
administrations produced similar findings from sensors situated
contralateral to each other in this region. NO  signals in  the left
hemispheres (−16 ± 3 pA, n = 2)  displayed no significant difference
(p > 0.05) from those situated in  the right hemisphere (−18 ± 4  pA,
n  = 4) of the accumbens. These findings confirm that there are no
significant differences observed between NO signals recorded in
opposite hemispheres confirming the viability of the Nafion®(5/2)-
modified Pt sensors in contralateral investigations in the rat brain.
All  of the aforementioned illustrate the complexity of NO deter-
minations utilising both direct and indirect analytical methods.
However, it is our understanding that this report provides the
first extensive and in depth comparison of real-time investigations
detailing the variations in endogenous NO determined in  a  variety
Fig. 5. Comparison of the effect of  saline (top), l-arginine (middle) and l-NAME
(bottom) on  Nafion®(5/2)-modified Pt sensor signal recorded in striatum, prefrontal
cortex (PFC) and nucleus accumbens (NA). Data is expressed as  mean I ±  SEM as
compared to baseline. (top)  denotes a significant difference between striatum
and nucleus accumbens (p < 0.05) and (bottom)  denotes a significant difference
between striatum and prefrontal cortex (p < 0.01) and between striatum and  nucleus
accumbens (p  < 0.01).
of brain regions. The Nafion®(5/2)-modified Pt NO sensor detailed
within  possesses the necessary sensitivity, spatial and temporal
precision for specific applications in animal model studies.
4.  Conclusion
We  have reported the in vivo characterisation of a  Nafion®(5/2)-
modified Pt NO sensor in  the prefrontal cortex and nucleus accum-
bens of freely moving rats. Previously we have demonstrated the
efficacy of the NO sensor in the striatum using local and systemic
administrations. Saline injections caused transient increases in oxi-
dation current in both the prefrontal cortex and nucleus accumbens
against baseline levels which was  attributed to the stress of the
i.p. injection stimulating neuronal activation. l-Arginine injections
produced significant increases in  the NO signal in  both regions.
Systemic administrations of the non selective NOS inhibitor l-
NAME resulted in significant decreases in the recorded current
measured using the Nafion®(5/2)-modified Pt NO sensor. Ascorbate
selectivity studies confirmed minimal deterioration of  the Nafion®
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modified surface. A critical comparison of the in  vivo characteri-
sation undertaken in the striatum, prefrontal cortex and nucleus
accumbens identified significantly greater affects of administra-
tions on NO sensors implanted in the striatum than the other
two regions. However, no definitive explanation can be provided
for these interregional differences. In summary we have exten-
sively characterised a  highly selective and sensitive NO sensor in
three different regions that is capable of measuring physiologically
meaningful NO signals in real-time in  the brain extracellular fluid.
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